United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021

September 8, 2021 Auto Bot Clinical Trials, Pulmonary Arterial Hypertension, United Therapeutics 0

Shots:

  • The BREEZE study evaluates Tyvaso DPI vs nebulized Tyvaso in 51 patients with PAH who were transitioned from Tyvaso to Tyvaso DPI at a corresponding treprostinil dose
  • The results demonstrated safety and tolerance with improvements in 6MWD compared to baseline, improvements in overall satisfaction, PAH Impact & PROs. Additionally, 96% completed 3wks. treatment phase & 2 patients discontinued due to treatment-related AEs, no study drug-related serious AEs were observed
  • Tyvaso DPI is a drug-device combination therapy that contains a dry powder formulation of Tyvaso inhalation solution. Tyvaso DPI is currently under FDA’s review with an anticipated PDUFA date in Oct’21

Click here to­ read full press release/ article | Ref: United Therapeutics | Image: United Therapeutics

The post United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021 first appeared on PharmaShots.